New therapeutic approach for treating NAFLD/NASH

CMR CureDiab Metabolic Research GmbH

bt_bb_section_bottom_section_coverage_image

CureDiab high-tech start-up: Our vision

CMR CureDiab Metabolic Research GmbH is a recently established high-tech start-up in the pre-seed phase. As a spin-off from the German Diabetes Center, CureDiab operates high-tech labs integrated in the infrastructure of the center. The vision of the company is to establish a new therapeutic approach for treating NAFLD/NASH based on activation of the GABA-A ion channel. A corresponding patent application has been filed.

CureDiab also operates as CRO for multiple aspects of metabolic research based on the long-lasting expertise of the founder. Please contact us for consulting and any aspect of in vitro metabolic research.

THE CHALLENGE

State-of-the-art cell culture

Primary human cell culture models available for assesment of metabolic function

Wide Range of Lab Testing

All modern biochemical assays established, custom requests can be adapted.

In Vitro Testing of drugs

Downstream signaling, gene expression analysis and multiple assays using digital microscopy available

Stages of the fatty liver

Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease, affecting around 25% of the population worldwide.

The spectrum of NAFLD encompasses different abnormalities, ranging from a simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) with various degrees of inflammation, ballooning, necrosis, fibrosis, and ultimately, cirrhosis and hepatocellular carcinoma.

Since no pharmacological treatment has been approved for NAFLD, delineating the mechanisms underlying the pathogenesis of NAFLD is crucial to managing NAFLD and its comorbidities.

Realistic stages of a fatty liver -- 3D Rendering